KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Arbutus Biopharma (ABUS) over the last 13 years, with Q3 2025 value amounting to $11000.0.

  • Arbutus Biopharma's Depreciation & Amortization (CF) fell 9672.62% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $352000.0, marking a year-over-year decrease of 6638.01%. This contributed to the annual value of $1.4 million for FY2024, which is 28.49% down from last year.
  • Per Arbutus Biopharma's latest filing, its Depreciation & Amortization (CF) stood at $11000.0 for Q3 2025, which was down 9672.62% from $11000.0 recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Depreciation & Amortization (CF) peaked at $474000.0 during Q4 2021, and registered a low of $11000.0 during Q2 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $335250.0, with a median of $355500.0 in 2024.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 758.02% in 2023, then crashed by 9691.01% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $474000.0 in 2021, then fell by 27.64% to $343000.0 in 2022, then increased by 7.58% to $369000.0 in 2023, then fell by 8.94% to $336000.0 in 2024, then plummeted by 96.73% to $11000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $11000.0 in Q3 2025, compared to $11000.0 in Q2 2025 and $330000.0 in Q1 2025.